Full-Time

Associate Director

CMC Statistician

Vaxcyte

Vaxcyte

501-1,000 employees

Develops broad-spectrum vaccines for bacterial infections

Compensation Overview

$170k - $198k/yr

+ Equity

San Carlos, CA, USA

Remote

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Minitab
Python
SAS
Regression
Data Science
R
Biostatistics

Get referred to Vaxcyte

See people who can refer or advise you

Requirements
  • An MS or PhD in Statistics, Biostatistics, Applied Statistics, Mathematics, Data Science, or a related quantitative discipline, with 10 or more years of experience in the pharmaceutical or biotechnology industry. Other combinations of education and experience may be considered.
  • Significant hands-on experience in CMC statistics, including specification setting, Justification of Specifications preparation, analytical method evaluation, stability analysis, process validation, Process Performance Qualification, Continued Process Verification, and/or commercial manufacturing support.
  • Experience supporting BLA, MAA, IND, or major health authority submissions and responses.
  • Strong understanding of late-stage and commercial specification-setting principles, including clinical relevance, patient-centric justification, manufacturing experience, analytical capability, stability data, and lifecycle considerations.
  • Strong expertise in statistical methods used in CMC and analytical development, including regression, analysis of variance, design of experiments, equivalence testing, tolerance and prediction intervals, control charts, process capability, and stability or shelf-life modeling.
  • Proficiency with statistical software such as R, SAS, JMP, Python, Minitab, or equivalent tools.
  • Comprehensive understanding of relevant regulatory expectations and guidance, including FDA, EU, WHO, and ICH principles applicable to biologics, vaccines, specifications, analytical methods, validation, stability, and lifecycle management.
  • Significant experience authoring technical and regulatory-ready documents, including statistical reports, Justification of Specifications sections, protocols, validation reports, standard operating procedures, and CMC submission content.
  • Ability to explain complex statistical concepts clearly and influence cross-functional decisions in a fast-paced environment.
  • Strong strategic and analytical decision-making skills, including the ability to navigate ambiguity, prioritize competing demands, and implement practical, phase-appropriate, and compliant approaches.
  • Ability to work independently in a remote, matrixed, and highly collaborative environment.
Responsibilities
  • Serve as the CMC statistical lead for the Vaccine Specification Working Group, supporting specification-setting strategy for drug substance, drug product, intermediates, raw materials, release testing, stability testing, and in-process testing.
  • Develop statistical strategies for specification setting and Justification of Specifications using clinical experience, manufacturing experience, stability behavior, analytical variability, assay capability, and process capability.
  • Design and execute statistical analyses such as confidence intervals, prediction intervals, tolerance intervals, regression, analysis of variance, design of experiments, equivalence testing, trend analysis, control charts, and Cpk or process capability analyses.
  • Provide statistical input to late-stage development, Process Performance Qualification, BLA or MAA preparation, health authority responses, commercial readiness, and specification lifecycle management.
  • Author and review statistical sections of specification and Justification of Specifications documents, CMC technical reports, regulatory submission sections, and briefing materials.
  • Assess analytical method performance and method lifecycle changes, including precision, transfer or bridging, comparability, and the impact of analytical variability on specification decisions.
  • Partner with Process Development, Manufacturing Science and Technology, Stability, Quality Assurance, Regulatory Affairs, Manufacturing, and external partners to align statistical rationale with CMC control strategy and regulatory expectations.
  • Support Process Performance Qualification, Annual Product Review, and Continued Process Verification activities by evaluating process consistency, state of control, trends, internal control limits, and capability relative to proposed or registered specifications.
  • Translate complex statistical concepts into clear recommendations for cross-functional teams, senior leaders, and non-statistical stakeholders, and support audits, inspections, and health authority interactions as needed.
Desired Qualifications
  • Demonstrated experience supporting BLA submissions and responses.
  • Experience with vaccines, biologics, complex modalities, multivalent products, conjugates, or adjuvanted products.
  • Project management capability.

Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections such as pneumococcal disease, Group A Strep, and Shigella. Using a proprietary cell-free protein synthesis platform called XpressCF™, the company attaches bacterial components to carrier proteins to trigger an immune response without the limitations of traditional cell-based manufacturing. This technology allows Vaxcyte to include more bacterial strains in a single dose than its competitors, as seen in their lead candidate which targets 24 different strains. The company's goal is to protect children and adults from life-threatening infections by creating vaccines that overcome complex bacterial defense mechanisms.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Foster City, California

Founded

2013

Get referred to Vaxcyte

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • All three OPUS adult Phase 3 trials fully enrolled by August 2026, de-risking execution.
  • The FDA expanded VAX-31 Breakthrough Therapy designation in May 2025 to include pneumonia.
  • Thermo Fisher’s up-to-$1 billion agreement and Lonza manufacturing build support commercial readiness.

What critics are saying

  • VAX-31 OPUS-1 data shifted to October 2026, compressing launch timelines.
  • Q2 2026 burn reached $284.3 million, while cash funding depends on dilution.
  • Pfizer Prevnar 20 and Merck Capvaxive already control adult pneumococcal vaccination, threatening VAX-31 adoption.

What makes Vaxcyte unique

  • Vaxcyte’s XpressCF platform produced VAX-31, a 31-valent PCV, on September 10, 2026.
  • OPUS trials were finalized with FDA alignment for a planned BLA submission.
  • Thermo Fisher and Lonza manufacturing deals lock commercial capacity across U.S. and Europe.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Stock Options

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

-4%

2 year growth

-1%
Yahoo Finance
Sep 8th, 2026
Vaxcyte CFO surrenders shares for tax, company holds $2.5B cash against $605M loss

Vaxcyte's president and CFO Andrew Guggenhime disposed of 2,705 shares according to a recent SEC filing. The transaction involved shares surrendered to satisfy tax withholding obligations on vested restricted stock units, not a discretionary sale. Guggenhime retains approximately 164,000 shares valued at $10.12 million based on 2 September's market close. His holdings consist of 102,000 shares held directly and 61,850 shares held indirectly through ALG 2025 Grat Holdings LLC. The clinical-stage biotechnology company held $2.51 billion in cash and investments at the end of June. However, Vaxcyte reported a six-month net loss of $604.9 million, with second-quarter operating expenses reaching $302.8 million, up from $226.2 million the previous year. Vaxcyte's lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine, is currently in clinical trials. The company has a market capitalisation of $9 billion.

Yahoo Finance
Sep 8th, 2026
Vaxcyte CEO sells shares for tax purposes as biotech burns $284M ahead of pivotal vaccine trial

Vaxcyte CEO Grant Pickering disposed of 6,289 shares of common stock in a non-discretionary transaction to cover tax withholding obligations from vesting restricted stock units, according to an SEC filing. The shares were valued at approximately $385,000 based on a weighted average sale price of $61.20. The California-based clinical-stage biotechnology company is developing VAX-31, a 31-strain pneumococcal vaccine. Vaxcyte expects topline data in the fourth quarter from OPUS-1, its pivotal Phase 3 trial testing VAX-31 against Pfizer's Prevnar 20 and Merck's Capvaxive in approximately 4,000 adults aged 50 and older. The company burned $284.3 million in the June quarter alone, with research and development spending up 38% year-over-year to $267.9 million. Vaxcyte holds $2.5 billion in cash.

Yahoo Finance
Sep 6th, 2026
Vaxcyte posts $284M Q2 loss as three Phase 3 vaccine trials complete enrolment

Vaxcyte reported second-quarter results showing a net loss of $284.3 million, nearly double the $166.6 million loss from a year earlier. The clinical-stage vaccine maker has fully enrolled three Phase 3 trials for its lead pneumococcal candidate VAX-31, with 6,191 adults dosed across the studies. Research and development spending rose to $267.9 million from $194.2 million, driven by manufacturing preparation and trial costs. The company held $2.5 billion in cash and investments as of 30 June. The first major data readout from the OPUS-1 trial, comparing VAX-31 against Prevnar 20 and Capvaxive, is expected in the fourth quarter of 2026. Results from OPUS-2 and OPUS-3 will follow in the first half of 2027. Hedge fund ownership declined from 57 to 47 funds, whilst short interest stands at 10% of the float.

Yahoo Finance
Sep 3rd, 2026
Vaxcyte appoints ex-Pfizer vaccines CMO, narrows VAX-31 Phase 3 data timeline to October

Vaxcyte has appointed Luis Jodar and David McAvoy as chief medical officer and chief legal officer, respectively. The clinical-stage vaccine innovation company also narrowed its guidance for topline data from the VAX-31 adult Phase 3 OPUS-1 trial, now expecting results by the end of October 2026. Jodar joins from Pfizer, where he spent 17 years, most recently as senior vice president and chief medical officer for vaccines and infectious diseases. He led clinical development and regulatory strategy for programmes including Prevnar 13 and Prevnar 20. McAvoy previously served as chief legal officer at Teva. The appointments come as Vaxcyte prepares for its planned Biologics Licence Application submission and potential launch of VAX-31.

Yahoo Finance
Jun 1st, 2026
Vaxcyte completes VAX-31 Phase 3 trial enrollment, shares rise 8.7%

Vaxcyte shares rose 8.7% after completing enrollment for three Phase 3 adult trials of its VAX-31 pneumococcal vaccine candidate and a Phase 2 infant study. The company also announced plans to begin a Phase 1 adult trial for its VAX-A1 Group A Strep programme. The milestone reduces execution risk whilst advancing Vaxcyte's two-pillar strategy targeting both adult and paediatric pneumococcal markets. The company's narrative projects $224.6 million revenue by 2029, representing an earnings increase of approximately $794.7 million from current levels. Some analysts forecast Vaxcyte reaching $424 million revenue by 2029. Key near-term catalysts include OPUS-1 Phase 3 adult data readout, though higher research and manufacturing spending may pressure the company's cash runway before late-stage outcomes are determined.